These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4337048)

  • 1. A reliable and simple method for simultaneous determination of DOPA and 3-O-methyldopa in plasma and brain.
    Fahn S; Prasad AL; Delesie R
    Anal Biochem; 1972 Apr; 46(2):557-75. PubMed ID: 4337048
    [No Abstract]   [Full Text] [Related]  

  • 2. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.
    Curzon G; Kantamaneni BD; Trigwell J
    Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098
    [No Abstract]   [Full Text] [Related]  

  • 3. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 4. An improved method for the assay of dopa.
    Johnson JC; Gold GJ; Clouet DH
    Anal Biochem; 1973 Jul; 54(1):129-36. PubMed ID: 4737665
    [No Abstract]   [Full Text] [Related]  

  • 5. 3-O-methyl metabolites of catecholamines: automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa.
    Prasad AL; Fahn S
    Biochem Med; 1974 Feb; 9(2):136-47. PubMed ID: 4822034
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinsonism treated with 3-O-methyldopa.
    Calne DB; Reid JL; Vakil SD
    Clin Pharmacol Ther; 1973; 14(3):386-9. PubMed ID: 4698566
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fluroimetric determination of sub-micromolar amounts of DOPA in plasma].
    Geissbuehler F
    Clin Chim Acta; 1973 May; 45(4):423-7. PubMed ID: 4730212
    [No Abstract]   [Full Text] [Related]  

  • 8. The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique.
    Laverty R; Taylor KM
    Anal Biochem; 1968 Feb; 22(2):269-79. PubMed ID: 4868086
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 10. L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions.
    Davidson L; Lloyd K; Dankova J; Hornykiewicz O
    Experientia; 1971 Sep; 27(9):1048-9. PubMed ID: 5116129
    [No Abstract]   [Full Text] [Related]  

  • 11. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
    Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993
    [No Abstract]   [Full Text] [Related]  

  • 12. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of L-dopa in human serum.
    Dizdar N; Arstrand K; Kågedal B
    Biotechniques; 2002 Nov; 33(5):1000, 1002. PubMed ID: 12449374
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
    Beers MF; Stern M; Hurtig H; Melvin G; Scarpa A
    J Chromatogr; 1984 Dec; 336(2):380-4. PubMed ID: 6442301
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-induced changes of extracerebral dopa metabolism in man.
    Tissot R; Bartholini G; Pletscher A
    Arch Neurol; 1969 Feb; 20(2):187-90. PubMed ID: 5767016
    [No Abstract]   [Full Text] [Related]  

  • 17. Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.
    Rivera-Calimlim L
    Br J Pharmacol; 1974 Feb; 50(2):259-63. PubMed ID: 4425764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated specific fluorimetric methods for epinephrine and norepinephrine assay in a single biological extract.
    Peyrin L; Cottet-Emard JM
    Anal Biochem; 1973 Dec; 56(2):515-31. PubMed ID: 4765642
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopamine: mediator of brain polysome disaggregation after L-dopa.
    Weiss BF; Munro HN; Ordonez LA; Wurtman RJ
    Science; 1972 Aug; 177(4049):613-6. PubMed ID: 4403139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.